Pamir Atagunduz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pamir Atagunduz has a total of 327 co-authors. Here are the top co-authors by number of shared publications:
Haner Direskeneli
Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey
21 shared publicationsNevsun Inanc
Medical Faculty, Department of Rheumatology, Marmara University, Pendik, 34890, Istanbul, Turkey
7 shared publications- Sibel Zehra Aydin
Division of Rheumatology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
7 shared publications Meryem Can
Medical Faculty, Department of Rheumatology, Marmara University, Pendik, 34890, Istanbul, Turkey
6 shared publications- Nevsun Inanc
Marmara Üniversitesi
6 shared publications - Gulsen Ozen
University of Iowa Health Care
5 shared publications
Latest Publications
- Open Access
Frequency and Potential Disease-Modifying Role of MEFV Variants in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Case–Control Study
Background and Objectives: Familial Mediterranean Fever (MEFV) gene variants exhibit a high carrier frequency in the Turkish population and modulate clinical phenotypes through persistent low-grade innate immune activation. However, their role in myeloid malignancies—where aberrant inflammasome signaling contributes to immunopathogenesis—remains poorly defined. We aimed to investigate the carrier frequency and potential disease-modifying role of common MEFV variants in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Materials and Methods: In this retrospective case–control study, 80 clinical evaluations from 75 unique patients with myeloid malignancies (53 AML and 27 MDS, including 5 patients evaluated in both cohorts before and after leukemic transformation) and 186 healthy controls from the Turkish population were analyzed. Four established pathogenic exon 10 variants (M694V, V726A, M680I, and M694I) and two variants of uncertain significance (VUS; K695R and E148Q) were genotyped using rhAmp™ SNP Genotyping and polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) assays. Clinical characteristics, blastic progression, and survival outcomes were evaluated. Results: Overall MEFV variant carriage did not differ significantly between the unique patient cohort and healthy controls (24.0% [18/75] vs. 19.9% [37/186], p = 0.462; or 23.8% [19/80] across all disease evaluations, p = 0.479). In the MDS cohort (n = 27), 10 mutant alleles were detected in 9 unique patients (variant frequency: 37.0% vs. 19.9% in controls, p = 0.045; unique carrier frequency: 33.3% vs. 19.9%, p = 0.113), as one female MDS patient was a compound heterozygote (M694V/V726A). Stratified analysis revealed that this enrichment in MDS was driven by established pathogenic exon 10 variants (22.2% [6/27] vs. 9.1% [17/186], p = 0.041; allele frequency: 11.1% [6/54] vs. 4.6% [17/372], p = 0.047), whereas VUS frequencies were comparable (14.8% vs. 10.8%, p = 0.533). Within the MDS group, male patients showed an exploratory trend toward a higher carrier rate than females (60.0% [6/10] vs. 17.6% [3/17], Fisher’s exact p = 0.039). Conversely, MEFV variant frequency in AML mirrored that of controls (20.8% [11/53] vs. 19.9%, p = 0.890). Baseline clinical parameters and overall survival did not differ significantly by genotype, although MEFV-positive MDS patients exhibited a non-significant numerical trend toward a shorter interval to blast progression (12.7 vs. 36.2 months). Conclusions: Our findings provide exploratory, hypothesis-generating evidence suggesting a potential enrichment of pathogenic exon 10 MEFV variants in MDS—particularly among male patients—but not in AML. Given the small sample size and retrospective design, these observations require validation in larger multi-center cohorts, and future studies may explore whether MEFV genotyping offers clinical or prognostic utility in high-prevalence populations.
Open AccessFrequency and Potential Disease-Modifying Role of MEFV Variants in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Case–Control Study
Background and Objectives: Familial Mediterranean Fever (MEFV) gene variants exhibit a high carrier frequency in the Turkish population and modulate clinical phenotypes through persistent low-grade innate immune activation. However, their role in myeloid malignancies—where aberrant inflammasome signaling contributes to immunopathogenesis—remains poorly defined. We aimed to investigate the carrier frequency and potential disease-modifying role of common MEFV variants in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Materials and Methods: In this retrospective case–control study, 80 clinical evaluations from 75 unique patients with myeloid malignancies (53 AML and 27 MDS, including 5 patients evaluated in both cohorts before and after leukemic transformation) and 186 healthy controls from the Turkish population were analyzed. Four established pathogenic exon 10 variants (M694V, V726A, M680I, and M694I) and two variants of uncertain significance (VUS; K695R and E148Q) were genotyped using rhAmp™ SNP Genotyping and polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) assays. Clinical characteristics, blastic progression, and survival outcomes were evaluated. Results: Overall MEFV variant carriage did not differ significantly between the unique patient cohort and healthy controls (24.0% [18/75] vs. 19.9% [37/186], p = 0.462; or 23.8% [19/80] across all disease evaluations, p = 0.479). In the MDS cohort (n = 27), 10 mutant alleles were detected in 9 unique patients (variant frequency: 37.0% vs. 19.9% in controls, p = 0.045; unique carrier frequency: 33.3% vs. 19.9%, p = 0.113), as one female MDS patient was a compound heterozygote (M694V/V726A). Stratified analysis revealed that this enrichment in MDS was driven by established pathogenic exon 10 variants (22.2% [6/27] vs. 9.1% [17/186], p = 0.041; allele frequency: 11.1% [6/54] vs. 4.6% [17/372], p = 0.047), whereas VUS frequencies were comparable (14.8% vs. 10.8%, p = 0.533). Within the MDS group, male patients showed an exploratory trend toward a higher carrier rate than females (60.0% [6/10] vs. 17.6% [3/17], Fisher’s exact p = 0.039). Conversely, MEFV variant frequency in AML mirrored that of controls (20.8% [11/53] vs. 19.9%, p = 0.890). Baseline clinical parameters and overall survival did not differ significantly by genotype, although MEFV-positive MDS patients exhibited a non-significant numerical trend toward a shorter interval to blast progression (12.7 vs. 36.2 months). Conclusions: Our findings provide exploratory, hypothesis-generating evidence suggesting a potential enrichment of pathogenic exon 10 MEFV variants in MDS—particularly among male patients—but not in AML. Given the small sample size and retrospective design, these observations require validation in larger multi-center cohorts, and future studies may explore whether MEFV genotyping offers clinical or prognostic utility in high-prevalence populations.
- 8 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6)
Inflammatory back pain-like symptoms and MRI mimics of sacroiliitis in patients with anatomical variants of the sacroiliac joint: a cross-sectional study
Sacroiliac joint (SIJ) anatomical variants are common on MRI and may complicate interpretation by mimicking inflammatory sacroiliitis; however, their relationship with inflammatory back pain (IBP)-like symptom patterns is not well defined in patients without axial spondyloarthritis (axSpA). To characterize inflammatory back pain (IBP)-like symptom patterns and accompanying MRI findings that may mimic sacroiliitis in patients with chronic low back pain (CLBP) and sacroiliac joint (SIJ) anatomical variants who did not fulfill classification criteria for axial spondyloarthritis (axSpA). In this cross-sectional study, consecutive patients younger than 45 years at the time of SIJ MRI/clinical evaluation, with chronic low back pain lasting at least 3 months, who underwent SIJ MRI between September 2023 and September 2025 were retrospectively screened for predefined SIJ anatomical variants and lumbosacral transitional anomalies. Patients with lumbosacral transitional anomalies were excluded at the screening stage. Those with at least one SIJ anatomical variant were invited for a standardized clinical assessment in which IBP features were captured using a single questionnaire covering the Calin, Rudwaleit (Berlin), and ASAS IBP criteria. All participants were systematically assessed against the ASAS classification criteria for axial spondyloarthritis (axSpA), and those who fulfilled these criteria were excluded from the final analysis. SIJ MRIs were read independently by two radiologists blinded to clinical data; agreement for variant detection was almost perfect (κ = 0.90). Bone marrow edema (BME) was evaluated according to the ASAS/OMERACT definition of MRI findings highly suggestive of active sacroiliitis, and structural changes were also recorded. Of 260 screened patients with CLBP, SIJ anatomical variants were identified in 108/260 (41.5%). After exclusions (n = 20), 88 patients were included in the final analysis; 75/88 (85.2%) were female, with a median age of 36 years (Q1-Q3: 28-39) and a median symptom duration of 3.0 years (Q1-Q3: 1.6-9.8). IBP positivity varied by criteria set: 51.1% (Calin), 34.1% (Berlin), and 27.3% (ASAS). Variants were predominantly bilateral (76/88, 86.4%). Among 98 recorded variant findings, accessory joint (n = 27) and iliosacral complex (n = 25) were the most frequent. ASAS/OMERACT-positive BME was present in 10/88 patients (11.4%); structural lesions included sclerosis in 22/88 (25.0%), erosions in 7/88 (8.0%), and fat metaplasia in 5/88 (5.7%). HLA-B27 positivity was observed in 4/69 tested patients (5.8%), and median CRP was 3.2 mg/L (Q1-Q3: 1.0-7.0). In a non-axSpA, variant-positive cohort, IBP-like symptom patterns were common, whereas ASAS/OMERACT-positive BME was infrequent. SIJ variants may therefore complicate clinical judgment because of symptom overlap in young patients within the typical age range for axSpA onset. Although infrequent, imaging features that mimic inflammatory disease highlight the need for careful clinical correlation to avoid misclassification as axSpA.
- 8 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6)
Inflammatory back pain-like symptoms and MRI mimics of sacroiliitis in patients with anatomical variants of the sacroiliac joint: a cross-sectional study
Sacroiliac joint (SIJ) anatomical variants are common on MRI and may complicate interpretation by mimicking inflammatory sacroiliitis; however, their relationship with inflammatory back pain (IBP)-like symptom patterns is not well defined in patients without axial spondyloarthritis (axSpA). To characterize inflammatory back pain (IBP)-like symptom patterns and accompanying MRI findings that may mimic sacroiliitis in patients with chronic low back pain (CLBP) and sacroiliac joint (SIJ) anatomical variants who did not fulfill classification criteria for axial spondyloarthritis (axSpA). In this cross-sectional study, consecutive patients younger than 45 years at the time of SIJ MRI/clinical evaluation, with chronic low back pain lasting at least 3 months, who underwent SIJ MRI between September 2023 and September 2025 were retrospectively screened for predefined SIJ anatomical variants and lumbosacral transitional anomalies. Patients with lumbosacral transitional anomalies were excluded at the screening stage. Those with at least one SIJ anatomical variant were invited for a standardized clinical assessment in which IBP features were captured using a single questionnaire covering the Calin, Rudwaleit (Berlin), and ASAS IBP criteria. All participants were systematically assessed against the ASAS classification criteria for axial spondyloarthritis (axSpA), and those who fulfilled these criteria were excluded from the final analysis. SIJ MRIs were read independently by two radiologists blinded to clinical data; agreement for variant detection was almost perfect (κ = 0.90). Bone marrow edema (BME) was evaluated according to the ASAS/OMERACT definition of MRI findings highly suggestive of active sacroiliitis, and structural changes were also recorded. Of 260 screened patients with CLBP, SIJ anatomical variants were identified in 108/260 (41.5%). After exclusions (n = 20), 88 patients were included in the final analysis; 75/88 (85.2%) were female, with a median age of 36 years (Q1-Q3: 28-39) and a median symptom duration of 3.0 years (Q1-Q3: 1.6-9.8). IBP positivity varied by criteria set: 51.1% (Calin), 34.1% (Berlin), and 27.3% (ASAS). Variants were predominantly bilateral (76/88, 86.4%). Among 98 recorded variant findings, accessory joint (n = 27) and iliosacral complex (n = 25) were the most frequent. ASAS/OMERACT-positive BME was present in 10/88 patients (11.4%); structural lesions included sclerosis in 22/88 (25.0%), erosions in 7/88 (8.0%), and fat metaplasia in 5/88 (5.7%). HLA-B27 positivity was observed in 4/69 tested patients (5.8%), and median CRP was 3.2 mg/L (Q1-Q3: 1.0-7.0). In a non-axSpA, variant-positive cohort, IBP-like symptom patterns were common, whereas ASAS/OMERACT-positive BME was infrequent. SIJ variants may therefore complicate clinical judgment because of symptom overlap in young patients within the typical age range for axSpA onset. Although infrequent, imaging features that mimic inflammatory disease highlight the need for careful clinical correlation to avoid misclassification as axSpA.
- 15 July 2025
- Published by Springer Nature
- p. 147-162
A Deep-Learning Approach for Diagnosing and Grading Ankylosing Spondylitis Sacroiliitis by X-Ray Images
- 15 July 2025
- Published by Springer Nature
- p. 147-162
A Deep-Learning Approach for Diagnosing and Grading Ankylosing Spondylitis Sacroiliitis by X-Ray Images
- Open Access
- 25 June 2025
- Published by Caleo in Rheumatology Quarterly
- Vol. 3 (2) , 60-67
LONG-TERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: DATA FROM THE TURKBIO REGISTRY
Aim:Selecting the most effective treatment plan for a patient represents one of the most challenging issues in contemporary rheumatology. Clinicians must consider the long-term retention rate and the reasons for discontinuing candidate drugs.This study aimed to assess the drug survival of certolizumab pegol (CZP) in patients with axial spondyloarthritis (ax-SpA) and identify predictors for discontinuation. Material and Methods:Data on patient characteristics, demographics, diagnosis, disease duration, treatment, and outcomes have been collected from the Turkish Biological (TURKBIO) Registry since 2011. By December 2020, 410 ax-SpA patients, treated with CZP, were included. Assessment of disease activity parameters was conducted at baseline and at regular follow-up intervals throughout the study period. Additionally, drug retention rates were evaluated through Kaplan-Meier survival analysis over the observation period. Results:The analysis revealed that CZP demonstrates a high long-term retention rate in ax-SpA. At 36 months, the retention rate of CZP among patients with ax-SpA was 71.5%. During follow-up, 92 (22.4%) patients discontinued CZP treatment, with inefficacy being the main reason for discontinuation (58.7% of patients who discontinued therapy, n=54). Patients who discontinued CZP had significantly higher health assessment questionnaire, bath ankylosing spondylitis (AS) functional index, and bath AS disease activity index values compared to those who continued with CZP. They were relatively older, had longer symptom duration, and had a higher prevalence of uveitis. Compared to patients who continued with CZP, those who discontinued CZP were more frequently co-treated with non-steroidal anti-inflammatory drugs (NSAIDs) (68.5% vs. 53.1%), methotrexate (24.1% vs. 6.9%), sulfasalazine (38.9% vs. 12.6%), and leflunomide (5.6% vs. 0.6%). However, co-treatment with NSAIDs or conventional synthetic disease-modifying anti-rheumatic drugs did not increase the retention rate of CZP. Conclusion:Real-world data from the TURKBIO registry reveal that CZP exhibits a high long-term retention rate in patients diagnosed with ax-SpA.
- 25 June 2025
- Published by Caleo in Rheumatology Quarterly
- Vol. 3 (2) , 60-67
Open AccessLONG-TERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: DATA FROM THE TURKBIO REGISTRY
Aim:Selecting the most effective treatment plan for a patient represents one of the most challenging issues in contemporary rheumatology. Clinicians must consider the long-term retention rate and the reasons for discontinuing candidate drugs.This study aimed to assess the drug survival of certolizumab pegol (CZP) in patients with axial spondyloarthritis (ax-SpA) and identify predictors for discontinuation. Material and Methods:Data on patient characteristics, demographics, diagnosis, disease duration, treatment, and outcomes have been collected from the Turkish Biological (TURKBIO) Registry since 2011. By December 2020, 410 ax-SpA patients, treated with CZP, were included. Assessment of disease activity parameters was conducted at baseline and at regular follow-up intervals throughout the study period. Additionally, drug retention rates were evaluated through Kaplan-Meier survival analysis over the observation period. Results:The analysis revealed that CZP demonstrates a high long-term retention rate in ax-SpA. At 36 months, the retention rate of CZP among patients with ax-SpA was 71.5%. During follow-up, 92 (22.4%) patients discontinued CZP treatment, with inefficacy being the main reason for discontinuation (58.7% of patients who discontinued therapy, n=54). Patients who discontinued CZP had significantly higher health assessment questionnaire, bath ankylosing spondylitis (AS) functional index, and bath AS disease activity index values compared to those who continued with CZP. They were relatively older, had longer symptom duration, and had a higher prevalence of uveitis. Compared to patients who continued with CZP, those who discontinued CZP were more frequently co-treated with non-steroidal anti-inflammatory drugs (NSAIDs) (68.5% vs. 53.1%), methotrexate (24.1% vs. 6.9%), sulfasalazine (38.9% vs. 12.6%), and leflunomide (5.6% vs. 0.6%). However, co-treatment with NSAIDs or conventional synthetic disease-modifying anti-rheumatic drugs did not increase the retention rate of CZP. Conclusion:Real-world data from the TURKBIO registry reveal that CZP exhibits a high long-term retention rate in patients diagnosed with ax-SpA.
- Open Access
- 10 December 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1319-1326
High sacral slope, lumbar lordosis, and sacral slope-to-pelvic incidence ratio are associated with new bone formation in ankylosing spondylitis
Background/aim: Syndesmophyte formation appears to be site specific in Ankylosing spondylitis(AS),and new bone formation seems to occur in regions of micro-trauma that are prone to tensile forces.Pelvic and spinal parameters are unique for individuals. Pelvic tilt and sacral slope are important anatomical features that compensate in harmony in keeping the sagittal balance. After puberty, the sacral slope shapes the lumbar lordosis, whereas the pelvic incidence is set to an individual constant. This study aims to analyze the properties of pelvic parameters in AS patients with and without syndesmophyte formation in the spine after 15years of disease duration.Materials and methods:Whole spine radiographs of 104 AS patients and clinical data are analyzed according to radiographic damage in the spine.AS patients were grouped as with or without syndesmophytes. Patients with complete bridging in at least one vertebral unit were excluded. Sacral slope,pelvic tilt,pelvic incidence,and lumbar lordosis were measured. Results: The mean disease duration was 14.5 years, and 60% of AS patients were male. Groups were similar in terms of age, sex distribution,and disease duration. Although numerically higher in patients with syndesmophytes, the mean pelvic incidence of AS patients was not different between groups(55.2±13.6 vs. 57.2±15.4). The sacral slope was high in patients with lumbar syndesmophytes(p<.005).Conclusion:Sacral slope was significantly higher in patients with syndesmophytes, which in turn results in an increased lumbar lordosis. Our results imply that the individual shape of the spine affects the distribution of weight and tensile forces in AS, and some patients are possibly more prone to new bone formation due to altered repetitive micro-trauma in the general genetic background of AS.Prospective studies addressing this cross-sectional observation may contribute to the development of new treatment strategies addressing mechanical load and may aid in decreasing management cost of AS with the present biologic therapies targeting new bone formation.
- 10 December 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1319-1326
Open AccessHigh sacral slope, lumbar lordosis, and sacral slope-to-pelvic incidence ratio are associated with new bone formation in ankylosing spondylitis
Background/aim: Syndesmophyte formation appears to be site specific in Ankylosing spondylitis(AS),and new bone formation seems to occur in regions of micro-trauma that are prone to tensile forces.Pelvic and spinal parameters are unique for individuals. Pelvic tilt and sacral slope are important anatomical features that compensate in harmony in keeping the sagittal balance. After puberty, the sacral slope shapes the lumbar lordosis, whereas the pelvic incidence is set to an individual constant. This study aims to analyze the properties of pelvic parameters in AS patients with and without syndesmophyte formation in the spine after 15years of disease duration.Materials and methods:Whole spine radiographs of 104 AS patients and clinical data are analyzed according to radiographic damage in the spine.AS patients were grouped as with or without syndesmophytes. Patients with complete bridging in at least one vertebral unit were excluded. Sacral slope,pelvic tilt,pelvic incidence,and lumbar lordosis were measured. Results: The mean disease duration was 14.5 years, and 60% of AS patients were male. Groups were similar in terms of age, sex distribution,and disease duration. Although numerically higher in patients with syndesmophytes, the mean pelvic incidence of AS patients was not different between groups(55.2±13.6 vs. 57.2±15.4). The sacral slope was high in patients with lumbar syndesmophytes(p<.005).Conclusion:Sacral slope was significantly higher in patients with syndesmophytes, which in turn results in an increased lumbar lordosis. Our results imply that the individual shape of the spine affects the distribution of weight and tensile forces in AS, and some patients are possibly more prone to new bone formation due to altered repetitive micro-trauma in the general genetic background of AS.Prospective studies addressing this cross-sectional observation may contribute to the development of new treatment strategies addressing mechanical load and may aid in decreasing management cost of AS with the present biologic therapies targeting new bone formation.
- 9 July 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (11) , 2421-2430
Pelvic parameters as prognostic factors of radiographic progression in classical Ankylosing Spondylitis: A prospective follow-up data
Radiographic progression in Ankylosing spondylitis (AS) is driven by mechanical strain. A well-balanced spine provides a favorable weight distribution across the entheses. Pelvic parameters are useful in assessing the shape of the spine. The present study aimed to prospectively investigate the predictive value of pelvic parameters for radiographic progression in AS. This non-interventional, observational, and prospective study enrolled AS patients fulfilling the modified New York criteria (mNY) currently under follow-up in the MARS (MARmara Spondyloarthritis) outpatient clinics. The primary objective was to investigate the relationship between the baseline pelvic parameters and radiographic progression in the spine. Two trained radiologists (EB, OB) independently assessed the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). An orthopedic surgeon (AHA) and a radiologist (EB) derived the pelvic parameters. Patients with no bridging or bamboo spine were included in the final analysis. Risk assessment for radiographic progression, defined as a two-unit increase in mSASSS or developing a new syndesmophyte every two years, was done using uni- and multivariate logistic regression analyses. Radiographs of 69 AS patients were analyzed. The median (IQR 25–75) prospective follow-up was 47.7 (34.6–52.8) months. Only 33.3% (23/69) had radiographic progression. The pelvic tilt (PT) was lower in patients with radiographic progression (p = 0.037) and each degree of decrease in PT provided a 9% increase in risk for radiographic progression. Male patients were 7.5 times more likely to progress. Pelvic parameters provide a prognostic insight into the radiographic progression in AS. Our observations may aid in selecting patient-specific interventions in addition to anti-inflammatory treatments.
- 9 July 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (11) , 2421-2430
Pelvic parameters as prognostic factors of radiographic progression in classical Ankylosing Spondylitis: A prospective follow-up data
Radiographic progression in Ankylosing spondylitis (AS) is driven by mechanical strain. A well-balanced spine provides a favorable weight distribution across the entheses. Pelvic parameters are useful in assessing the shape of the spine. The present study aimed to prospectively investigate the predictive value of pelvic parameters for radiographic progression in AS. This non-interventional, observational, and prospective study enrolled AS patients fulfilling the modified New York criteria (mNY) currently under follow-up in the MARS (MARmara Spondyloarthritis) outpatient clinics. The primary objective was to investigate the relationship between the baseline pelvic parameters and radiographic progression in the spine. Two trained radiologists (EB, OB) independently assessed the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). An orthopedic surgeon (AHA) and a radiologist (EB) derived the pelvic parameters. Patients with no bridging or bamboo spine were included in the final analysis. Risk assessment for radiographic progression, defined as a two-unit increase in mSASSS or developing a new syndesmophyte every two years, was done using uni- and multivariate logistic regression analyses. Radiographs of 69 AS patients were analyzed. The median (IQR 25–75) prospective follow-up was 47.7 (34.6–52.8) months. Only 33.3% (23/69) had radiographic progression. The pelvic tilt (PT) was lower in patients with radiographic progression (p = 0.037) and each degree of decrease in PT provided a 9% increase in risk for radiographic progression. Male patients were 7.5 times more likely to progress. Pelvic parameters provide a prognostic insight into the radiographic progression in AS. Our observations may aid in selecting patient-specific interventions in addition to anti-inflammatory treatments.
- 27 November 2023
- Published by Galenos Yayinevi in Ulusal Romatoloji Dergisi
- Vol. 15 (3) , 154-161
Hypogammaglobulinemia and severe infection risk in patients with autoimmune diseases during rituximab treatment
- 27 November 2023
- Published by Galenos Yayinevi in Ulusal Romatoloji Dergisi
- Vol. 15 (3) , 154-161
Hypogammaglobulinemia and severe infection risk in patients with autoimmune diseases during rituximab treatment
- Open Access
- 30 September 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (3) , 347-357
Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database
Objectives: This study aimed to evaluate the hepatitis B (HBV) and C (HCV) frequency and clinical characteristics among patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) who receive biological treatments. Patients and methods: The observational study was conducted with patients from the TReasure database, a web-based prospective observational registry collecting data from 17 centers across Türkiye, between December 2017 and June 2021. From this database, 3,147 RA patients (2,502 males, 645 females; median age 56 years; range, 44 to 64 years) and 6,071 SpA patients (2,709 males, 3,362 females; median age 43 years; range, 36 to 52 years) were analyzed in terms of viral hepatitis, patient characteristics, and treatments used. Results: The screening rate for HBV was 97% in RA and 94.2% in SpA patients. Hepatitis B surface antigen (HBsAg) positivity rates were 2.6% and 2%, hepatitis B surface antibody positivity rates were 32.3% and 34%, hepatitis B core antibody positivity rates were 20.3% and 12.5%, HBV DNA (deoxyribonucleic acid) positivity rates were 3.5% and 12.5%, and antibody against HCV positivity rates were 0.8% and 0.3% in RA and SpA patients, respectively. The HBsAg-positive patients were older and had more comorbidities, including hypertension, diabetes, and coronary artery disease. In addition, rheumatoid factor (RF) positivity was more common in HBsAg-positive cases. The most frequently prescribed biologic disease-modifying antirheumatic drugs were adalimumab (28.5%), etanercept (27%), tofacitinib (23.4%), and tocilizumab (21.5%) in the RA group and adalimumab (48.1%), etanercept (31.4%), infliximab (22.6%), and certolizumab (21.1%) in the SpA group. Hepatitis B reactivation was observed in one RA patient during treatment, who received rituximab and prophylaxis with tenofovir. Conclusion: The epidemiological characteristics of patients with rheumatic diseases and viral hepatitis are essential for effective patient management. This study provided the most recent epidemiological characteristics from the prospective TReasure database, one of the comprehensive registries in rheumatology practice.
- 30 September 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (3) , 347-357
Open AccessEpidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database
Objectives: This study aimed to evaluate the hepatitis B (HBV) and C (HCV) frequency and clinical characteristics among patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) who receive biological treatments. Patients and methods: The observational study was conducted with patients from the TReasure database, a web-based prospective observational registry collecting data from 17 centers across Türkiye, between December 2017 and June 2021. From this database, 3,147 RA patients (2,502 males, 645 females; median age 56 years; range, 44 to 64 years) and 6,071 SpA patients (2,709 males, 3,362 females; median age 43 years; range, 36 to 52 years) were analyzed in terms of viral hepatitis, patient characteristics, and treatments used. Results: The screening rate for HBV was 97% in RA and 94.2% in SpA patients. Hepatitis B surface antigen (HBsAg) positivity rates were 2.6% and 2%, hepatitis B surface antibody positivity rates were 32.3% and 34%, hepatitis B core antibody positivity rates were 20.3% and 12.5%, HBV DNA (deoxyribonucleic acid) positivity rates were 3.5% and 12.5%, and antibody against HCV positivity rates were 0.8% and 0.3% in RA and SpA patients, respectively. The HBsAg-positive patients were older and had more comorbidities, including hypertension, diabetes, and coronary artery disease. In addition, rheumatoid factor (RF) positivity was more common in HBsAg-positive cases. The most frequently prescribed biologic disease-modifying antirheumatic drugs were adalimumab (28.5%), etanercept (27%), tofacitinib (23.4%), and tocilizumab (21.5%) in the RA group and adalimumab (48.1%), etanercept (31.4%), infliximab (22.6%), and certolizumab (21.1%) in the SpA group. Hepatitis B reactivation was observed in one RA patient during treatment, who received rituximab and prophylaxis with tenofovir. Conclusion: The epidemiological characteristics of patients with rheumatic diseases and viral hepatitis are essential for effective patient management. This study provided the most recent epidemiological characteristics from the prospective TReasure database, one of the comprehensive registries in rheumatology practice.
- 1 December 2022
- Published by Galenos Yayinevi in Ulusal Romatoloji Dergisi
- Vol. 14 (3) , 117-123
Cardiovascular risk assessment after anti-TNF treatment in patients with rheumatoid arthritis and ankylosing spondylitis with Strain Echocardiography
- 1 December 2022
- Published by Galenos Yayinevi in Ulusal Romatoloji Dergisi
- Vol. 14 (3) , 117-123
Cardiovascular risk assessment after anti-TNF treatment in patients with rheumatoid arthritis and ankylosing spondylitis with Strain Echocardiography
- 23 August 2022
- Published by Elsevier in Clinical Imaging
- Vol. 92, 19-24
Presence of axial spondyloarthritis associated sacroiliitis and structural changes on MR enterography: A direct comparison with sacroiliac joint MRI
- 23 August 2022
- Published by Elsevier in Clinical Imaging
- Vol. 92, 19-24
Presence of axial spondyloarthritis associated sacroiliitis and structural changes on MR enterography: A direct comparison with sacroiliac joint MRI